Dogwood Therapeutics Inc. (DWTX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript
Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment
Dogwood Therapeutics NASDAQ: DWTX said its Phase 2b study of Halneuron, an investigational treatment for chemotherapy-induced neuropathic pain, has enrolled more than 230 patients and is expected to report top-line data later this fall.
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
Dogwood Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 3.13M | $6.61M | $3.99M | -$2.62M | -39.57% |
 Sima Elimelech Activest Wealth Management | 120 | $298.8 | $150 | -$148.8 | -49.8% |
Dogwood Therapeutics Inc. (DWTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Dogwood Therapeutics Inc. ever had a stock split?
Dogwood Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Gregory Duncan CEO | NASDAQ (CM) Exchange | 92829J203 CUSIP |
| US Country | 8 Employees | - Last Dividend | 9 Oct 2024 Last Split | - IPO Date |
Overview
Dogwood Therapeutics, Inc. is a development-stage biotechnology company with a focus on creating innovative antiviral therapies aimed at treating diseases linked to a viral-induced abnormal immune response. Originally established as Virios Therapeutics, Inc., the company underwent a name change to Dogwood Therapeutics, Inc. in October 2024. Since its inception in 2012, Dogwood Therapeutics has been dedicated to advancing its research and development efforts from its headquarters in Alpharetta, Georgia. With its expertise in antiviral therapies, Dogwood Therapeutics aims to address unmet medical needs in the treatment of viral-related conditions and their associated immune responses.
Products and Services
Dogwood Therapeutics, Inc. is involved in the development of two main antiviral therapy candidates:
- IMC-1: This lead development candidate represents a fixed dose combination of famciclovir and celecoxib. It is specifically designed to treat fibromyalgia, focusing on alleviating the complex symptoms associated with the condition. The innovative combination aims to target the underlying viral triggers and abnormal immune responses believed to play a role in fibromyalgia.
- IMC-2: The second development candidate, IMC-2, is a combination therapy comprising valacyclovir and celecoxib. It is being developed for the management of various long COVID symptoms, including fatigue, sleep disturbances, attention deficits, pain, issues in autonomic function, and anxiety. By addressing these symptoms, IMC-2 aims to improve the quality of life for individuals suffering from the long-term effects of COVID-19, targeting the viral and inflammatory aspects of the condition.
Contact Information
